Mycophenolate mofetil in multiple sclerosis

被引:60
作者
Frohman, EM
Brannon, K
Racke, MK
Hawker, K
机构
[1] Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75235 USA
[2] Univ Texas, SW Med Ctr, Dept Opthalmol, Dallas, TX 75235 USA
[3] Univ Texas, SW Med Ctr, Ctr Immunol, Dallas, TX 75235 USA
关键词
mycophenolate; inosine monophosphate dehydrogenase; lymphocytes; multiple sclerosis;
D O I
10.1097/00002826-200403000-00006
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To describe experience with the use of mycophenolate mofetil (MMF) in the treatment of multiple sclerosis (MS). Background: MMF is a potent immunosuppressant that is a selective inhibitor of inosine 5'-monophosphate dehydrogenase type II, the enzyme responsible for the de novo synthesis of the purine nucleotide guanine within activated T and B lymphocytes and macrophages. Methods: A retrospective review of experience in treating 79 MS patients with MMF (61 with secondary progressive, 14 with relapsing-remitting, and 4 with primary progressive MS) in the authors' MS center. Results: in most cases, MMF was added as adjunctive therapy in patients already being treated with either interferon-beta (n = 44) or glatiramer acetate (n = 20). Fifteen patients not able to use interferon or glatiramer acetate were treated with MMF monotherapy. Seventy percent of the patients continued MMF therapy. Eight patients discontinued therapy because of side effects, 7 patients continued to exhibit evidence of disease progression, 4 were denied insurance coverage, 2 were lost to follow-up, and 1 patient had an elevation of hepatic transaminases that resolved on discontinuation of MMF. One patient discontinued MMF therapy secondary to cytomegalovirus diarrhea. Conclusion: MMF was well tolerated by the majority of patients treated. While these clinical observations were uncontrolled, the clinical course of MS was either unchanged or subjectively improved in many of the treated patients. A randomized controlled trial of MMF in MS, either as monotherapy or in conjunction with interferon or glatiramer acetate, appears warranted.
引用
收藏
页码:80 / 83
页数:4
相关论文
共 25 条
  • [1] Mycophenolate-mofetil in the treatment of refractory multiple sclerosis
    Ahrens, N
    Salama, A
    Haas, J
    [J]. JOURNAL OF NEUROLOGY, 2001, 248 (08) : 713 - 714
  • [2] Combined mycophenolate mofetil and cyclosporin therapy for severe recalcitrant psoriasis
    Ameen, M
    Smith, HR
    Barker, JNWN
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2001, 26 (06) : 480 - 483
  • [3] Novel assays of multiple lymphocyte functions in whole blood measure - New mechanisms of action of mycophenolate mofetil in vivo
    Barten, MJ
    van Gelder, T
    Gummert, JF
    Shorthouse, R
    Morris, RE
    [J]. TRANSPLANT IMMUNOLOGY, 2002, 10 (01) : 1 - 14
  • [4] Pharmacodynamics of mycophenolate mofetil after heart transplantation: New mechanisms of action and correlations with histologic severity of graft rejection
    Barten, MJ
    van Gelder, T
    Gummert, JF
    Boeke, K
    Shorthouse, R
    Billingham, ME
    Morris, RE
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) : 719 - 732
  • [5] Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
    Chaudhry, V
    Cornblath, DR
    Griffin, JW
    O'Brien, R
    Drachman, DB
    [J]. NEUROLOGY, 2001, 56 (01) : 94 - 96
  • [6] Mycophenolate mofetil for myasthenia gravis: An open-label pilot study
    Ciafaloni, E
    Massey, JM
    Tucker-Lipscomb, B
    Sanders, DB
    [J]. NEUROLOGY, 2001, 56 (01) : 97 - 99
  • [7] Mycophenolate mofetil for the treatment of Takayasu arteritis: Report of three cases
    Daina, E
    Schieppati, A
    Remuzzi, G
    [J]. ANNALS OF INTERNAL MEDICINE, 1999, 130 (05) : 422 - 426
  • [8] Gelber AC, 2000, J RHEUMATOL, V27, P1542
  • [9] Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil
    Hauser, RA
    Malek, AR
    Rosen, R
    [J]. NEUROLOGY, 1998, 51 (03) : 912 - 913
  • [10] Mycophenolate mofetil suppresses the production of anti-blood type anitbodies after renal transplantation across the ABO blood barrier: ELISA to detect humoral activity
    Ishida, H
    Tanabe, K
    Furusawa, M
    Ishizuka, T
    Shimmura, H
    Tokumoto, T
    Hayashi, T
    Toma, H
    [J]. TRANSPLANTATION, 2002, 74 (08) : 1187 - 1189